Tag:
Dendreon
Latest Headlines
Latest Headlines
SPOTLIGHT: Dendreon faces probe
Add the SEC to the list of problems faced by Dendreon. Regulators have begun an informal
Provenge delay triggers furor among cancer victims
The FDA's decision to delay approving Provenge until Dendreon can provide additional efficacy data has triggered intense anger among patients desperate to get the vaccine, which is designed to allow patients to live longer with advanced prostate cancer by stimulating their immune systems. The FDA's delay was at least partly attributed to the opinions of two top oncologists who …
Analysts see a continuing surge of licensing deals
Merck officials would probably be among the first to agree with Needham & Associates' conclusion that the pace of biotech partnerships shows no sign of letting up. Big Pharma and Big Biotech are both avid about doing more deals to fill their pipelines. Among some of the biggest partnership deals that are likely in the works right now, they say, is a pact for Dendreon's Provenge, Dyax's …
ALSO NOTED: Emisphere fires CEO; Crucell in new antibody pact; Watson touts Phase III results; and much more...
> Chutes & Ladders: Emisphere Technologies has fired its chairman and CEO, Dr. Michael Goldberg, without citing a reason for his dismissal. Lewis Bender, senior vice president of business development, takes over in the interim. Report > Crucell has inked a development deal with Novo Nordisk to develop new antibodies. …
ALSO NOTED: Cancer vaccine market to soar; Point Therapeutics cuts staff; and much more...
> Analysts say that the cancer vaccine market will soar to $8 billion by 2012. Report > Fledgling Point Therapeutics has cut its workforce by 15 percent, with most of the cuts focused on its preclinical development group. "In our ongoing efforts to further talabostat's clinical development, particularly our Phase III program, it became necessary for Point to undertake measures to reduce our …
SPOTLIGHT: Dendreon advances Provenge app
Dendreon says it has submitted two of the three sections required in its rolling application for the cancer drug Provenge. The chemistry, manufacturing and controls section of the application is scheduled to be filed later this year. Dendreon is seeking fast-track approval of Provenge for advanced prostate cancer patients whose cancer has spread. Report
C&L: Berendt tapped to run Aegera
Aegera Therapeutics has appointed Dr. Michael J. Berendt as the company's president and CEO. Ablynx Chairman Dr Edwin Moses has accepted the board's offer to extend his role to include that of CEO. Quintiles Transnational has appointed Yoh Narimatsu president and CEO of Quintiles …
C&L: Leiden steps down from Abbott group
Abbott Laboratories announced Jeffrey M. Leiden is resigning as president and COO of the company's pharmaceutical products group. Abbott said Richard A. Gonzalez will take his place as president and COO on March 27. Gonzalez is currently president and COO of Abbott's medical products division. La Jolla Pharmaceutical …
Dendreon cuts jobs, focuses on Provenge
Dendreon has announced that it will cut 34 jobs as it refocuses its resources on advancing its lead investigational drug Provenge to market. Provenge is a cellular immunotherapy for the treatment of prostate cancer. In addition, the company announced that Michelle Burris, senior vice president and CFO, will be leaving. Rick Hamm, senior vice president, corporate development and general counsel will oversee financial functions and David Urdal, Ph.D., senior vice president and chief …
C&L: Solvay Canada picks Jobson to lead
Solvay Pharma, Canada, has appointed Graham Jobson as president and CEO. Mr. Jobson replaces Dr. Laurence Downey who held the position for six years. Previously, Mr. Jobson was president and CEO of Montreal-based Fournier Pharma. Aperon Biosystems has appointed Richard A. Lotti as its president CEO. Most recently, he was …
